Top

Published in:

Open Access 01-12-2021 | NSCLC | Research

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

Authors: Piera Gargiulo, Laura Arenare, Cesare Gridelli, Alessandro Morabito, Fortunato Ciardiello, Vittorio Gebbia, Paolo Maione, Alessia Spagnuolo, Giuliano Palumbo, Giovanna Esposito, Carminia Maria Della Corte, Floriana Morgillo, Gianfranco Mancuso, Raimondo Di Liello, Adriano Gravina, Clorinda Schettino, Massimo Di Maio, Ciro Gallo, Francesco Perrone, Maria Carmela Piccirillo

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Chemotherapy-induced neutropenia (CIN) has been demonstrated to be a prognostic factor in several cancer conditions. We previously found a significant prognostic value of CIN on overall survival (OS), in a pooled dataset of patients with advanced non-small-cell lung cancer (NSCLC) receiving first line chemotherapy from 1996 to 2001. However, the prognostic role of CIN in NSCLC is still debated.

Methods

We performed a post hoc analysis pooling data prospectively collected in six randomized phase 3 trials in NSCLC conducted from 2002 to 2016. Patients who never started chemotherapy and those for whom toxicity data were missing were excluded. Neutropenia was categorized on the basis of worst grade during chemotherapy: absent (grade 0), mild (grade 1–2), or severe (grade 3–4). The primary endpoint was OS. Multivariable Cox model was applied for statistical analyses. In the primary analysis, a minimum time (landmark) at 180 days from randomization was applied in order to minimize the time-dependent bias.

Results

Overall, 1529 patients, who received chemotherapy, were eligible; 572 of them (who received 6 cycles of treatment) represented the landmark population. Severe CIN was reported in 143 (25.0%) patients and mild CIN in 135 (23.6%). At multivariable OS analysis, CIN was significantly predictive of prognosis although its prognostic value was entirely driven by severe CIN (hazard ratio [HR] of death 0.71; 95%CI: 0.53–0.95) while it was not evident with mild CIN (HR 1.21; 95%CI: 0.92–1.58). Consistent results were observed in the out-of-landmark group (including 957 patients), where both severe and mild CIN were significantly associated with a reduced risk of death.

Conclusion

The pooled analysis of six large trials of NSCLC treatment shows that CIN occurrence is significantly associated with a longer overall survival, particularly in patients developing severe CIN, confirming our previous findings.

Available only for authorised users

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–237.CrossRef

Kasi PM, Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78(7):737–45. https://doi.org/10.1007/s40265-018-0909-3.CrossRefPubMed

Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–7. https://doi.org/10.1007/s00280-010-1487-6.CrossRefPubMed

Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6(9):669–77. https://doi.org/10.1016/S1470-2045(05)70255-2.CrossRefPubMed

Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86(8):1297–302. https://doi.org/10.1038/sj.bjc.6600139.CrossRefPubMedPubMedCentral

Lee CY, Park SY, Shin TR, Park YB, Kim CH, Jang SH, et al. Early-onset neutropenia during perioperative chemotherapy is predictive of increased survival in patients with completely resected non-small cell lung cancer: a retrospective analysis. Anticancer Res. 2013;33(6):2755–61.PubMed

Jang SH, Kim SY, Kim JH, Park S, Hwang YI, Kim DG, et al. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients. J Cancer Res Clin Oncol. 2013;139(3):409–17. https://doi.org/10.1007/s00432-012-1341-9.CrossRefPubMed

Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Taron M, et al. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2011;12(4):224–30. https://doi.org/10.1016/j.cllc.2011.03.023.CrossRefPubMed

Brunetto AT, Carden CP, Myerson J, Faria AL, Ashley S, Popat S, et al. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy. J Thorac Oncol. 2010;5(9):1397–403. https://doi.org/10.1097/JTO.0b013e3181eba7f9.CrossRefPubMed

10.

Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–52. https://doi.org/10.1093/jnci/djp335.CrossRefPubMedPubMedCentral

11.

Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Vigano MG, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2010;67(1):86–92. https://doi.org/10.1016/j.lungcan.2009.03.021.CrossRefPubMed

12.

Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 2007;8(6):500–12. https://doi.org/10.1016/S1470-2045(07)70146-8.CrossRefPubMed

13.

Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012;30(24):3002–11. https://doi.org/10.1200/JCO.2011.41.2056.CrossRefPubMed

14.

Gridelli C, De Maio E, Barbera S, Sannicolo M, Piazza E, Piantedosi F, et al. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Lung Cancer. 2008;61(1):67–72. https://doi.org/10.1016/j.lungcan.2007.12.002.CrossRefPubMed

15.

Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, Bearz A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007;25(29):4663–9. https://doi.org/10.1200/JCO.2007.12.5708.CrossRefPubMed

16.

Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, et al. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials. J Clin Oncol. 2018;36(25):2585–92. https://doi.org/10.1200/JCO.2017.76.8390.CrossRefPubMed

17.

Kishida Y, Kawahara M, Teramukai S, Kubota K, Komuta K, Minato K, et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan multinational trial organization LC00-03. Br J Cancer. 2009;101(9):1537–42. https://doi.org/10.1038/sj.bjc.6605348.CrossRefPubMedPubMedCentral

18.

Luciani A, Bertuzzi C, Ascione G, Di Gennaro E, Bozzoni S, Zonato S, et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2009;66(1):94–6. https://doi.org/10.1016/j.lungcan.2008.12.019.CrossRefPubMed

19.

Newell DR. Getting the right dose in cancer chemotherapy--time to stop using surface area? Br J Cancer. 2002;86(8):1207–8. https://doi.org/10.1038/sj.bjc.6600226.CrossRefPubMedPubMedCentral

20.

Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol. 2012;214:411–42.CrossRef

21.

Wang L, Cao Y, Ren M, Chen A, Cui J, Sun D, et al. Sex differences in Hazard ratio during drug treatment of non-small-cell lung cancer in major clinical trials: a focused data review and meta-analysis. Clin Ther. 2017;39(1):34–54. https://doi.org/10.1016/j.clinthera.2016.12.008.CrossRefPubMed

22.

Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850–6. https://doi.org/10.1200/JCO.2005.03.171.CrossRefPubMed

23.

Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer. 2008;62(3):356–63. https://doi.org/10.1016/j.lungcan.2008.03.030.CrossRefPubMed

24.

Kasi PM, Koep T, Schnettler E, Shahjehan F, Kamatham V, Baldeo C, et al. Feasibility of integrating panel-based pharmacogenomics testing for chemotherapy and supportive care in patients with colorectal cancer. Technol Cancer Res Treat. 2019;18:1533033819873924.CrossRef

25.

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>a/HapB3, and c.1601G>a as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639–50. https://doi.org/10.1016/S1470-2045(15)00286-7.CrossRefPubMed

26.

Campbell JM, Stephenson MD, Bateman E, Peters MD, Keefe DM, Bowen JM. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J. 2017;17(1):21–8. https://doi.org/10.1038/tpj.2016.58.CrossRefPubMed

27.

Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, et al. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet. 2016;31(1):90–4. https://doi.org/10.1016/j.dmpk.2015.12.004.CrossRefPubMed

28.

Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, et al. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018;18(1):35–42. https://doi.org/10.1038/tpj.2016.75.CrossRefPubMed

29.

Uchiyama T, Kanno H, Ishitani K, Fujii H, Ohta H, Matsui H, et al. An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel. Cancer Chemother Pharmacol. 2012;69(6):1617–24. https://doi.org/10.1007/s00280-012-1872-4.CrossRefPubMed

30.

Nieuweboer AJ, Smid M, de Graan AJ, Elbouazzaoui S, de Bruijn P, Martens JW, et al. Predicting paclitaxel-induced neutropenia using the DMET platform. Pharmacogenomics. 2015;16(11):1231–41. https://doi.org/10.2217/pgs.15.68.CrossRefPubMed

31.

Morabito A, Daniele G, Costanzo R, Favaretto AG, Filipazzi V, Rossi A, et al. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: the small-cell-lung cancer toxicity adjusted dosing (STAD-1) trial. Lung Cancer. 2017;108:15–21. https://doi.org/10.1016/j.lungcan.2017.02.016.CrossRefPubMed

32.

Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrom M, Karlsson P, et al. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol. 2011;50(1):35–41. https://doi.org/10.3109/0284186X.2010.535847.CrossRefPubMed

33.

Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast Cancer: a randomized clinical trial. JAMA. 2016;316(18):1888–96. https://doi.org/10.1001/jama.2016.15865.CrossRefPubMed

34.

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2019;30(1):109–14. https://doi.org/10.1093/annonc/mdy475.CrossRefPubMed

Title: Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
Authors: Piera Gargiulo
Laura Arenare
Cesare Gridelli
Alessandro Morabito
Fortunato Ciardiello
Vittorio Gebbia
Paolo Maione
Alessia Spagnuolo
Giuliano Palumbo
Giovanna Esposito
Carminia Maria Della Corte
Floriana Morgillo
Gianfranco Mancuso
Raimondo Di Liello
Adriano Gravina
Clorinda Schettino
Massimo Di Maio
Ciro Gallo
Francesco Perrone
Maria Carmela Piccirillo
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: NSCLC
Lung Cancer
Lung Cancer
Neutropenia
NSCLC
Lung Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08323-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Prediction of ipsilateral lateral cervical lymph node metastasis in papillary thyroid carcinoma: a combined dual-energy CT and thyroid function indicators study

Infrequent RAS mutation is not associated with specific histological phenotype in gliomas

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Keynote webinar | Spotlight on antibody–drug conjugates in cancer